Skip to content
Clinical Trials – home

Servico de Saude da Regiao Autonoma Da Madeira EPERAM

Research site

Portugal Avenida Luis De Camoes Nº 57, 9004-514 Funchal, Portugal

  • 8 trials recruiting
  • Alpha-1 antitrypsin deficiency · Acute myeloid leukaemia · Chronic kidney disease
  • Adult patients

About Specializations

Servico de Saude da Regiao Autonoma Da Madeira EPERAM in Funchal, Portugal specialises in clinical trials of conditions such as Alpha-1 antitrypsin deficiency, Acute myeloid leukaemia, Chronic kidney disease, Congenital cystic kidney disease, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive and Liver Disease Research

At Servico de Saude da Regiao Autonoma Da Madeira EPERAM in Funchal, clinical research in digestive system diseases focuses on liver conditions such as alpha-1 antitrypsin deficiency-associated liver disease and primary biliary cholangitis. These studies are designed to assess new treatment options and better understand how therapies may slow disease progression and improve liver health.

  • Alpha-1 antitrypsin deficiency-associated liver disease
  • Primary biliary cholangitis
  • Testing treatments aimed at reducing liver scarring and improving long-term outcomes

Work in this area also reflects interest in broader nutritional and metabolic diseases, showing a strong focus on chronic conditions that affect liver function and overall metabolism.

Kidney and Urinary Health Studies

Research in reproductive and urinary physiological phenomena and nutritional and metabolic diseases includes studies of autosomal dominant polycystic kidney disease and chronic kidney disease. The main goal is to evaluate treatments that may help protect kidney function, reduce complications, and delay worsening of disease.

  • Autosomal dominant polycystic kidney disease
  • Chronic kidney disease
  • Evaluating therapies that may slow kidney decline and support cardiorenal health

These trials highlight a practical focus on long-term disease management and improving patient outcomes in chronic kidney disorders.

Neurology and Movement Disorder Trials

The Serviço de Neurologia is also involved in nervous system diseases research, including studies in early-stage Parkinson’s disease. This work is centered on testing treatments that may help preserve function, manage symptoms, and potentially influence disease progression.

  • Early-stage Parkinson’s disease
  • Testing a therapy aimed at improving disease control in the early stages
  • Exploring ways to support neurological health and patient independence

The site’s neurology activity shows an interest in therapies for progressive brain disorders where early intervention may be especially important.

Oncology and Cancer Treatment Research

Clinical trials in neoplasms at this hospital include research in metastatic non-small cell lung cancer and advanced melanoma. These studies are aimed at comparing new cancer therapies with existing treatment approaches and evaluating whether they can improve survival and disease control.

  • Metastatic non-small cell lung cancer
  • Previously untreated advanced melanoma
  • Assessing new cancer treatments and comparing effectiveness with standard care

This oncology portfolio reflects a strong interest in expanding treatment options for advanced cancers where better outcomes are urgently needed.

Broader Chronic Disease and Treatment Evaluation

Across multiple therapeutic areas, the research at Servico de Saude da Regiao Autonoma Da Madeira EPERAM includes studies that examine safety, tolerability, and real-world benefit of emerging therapies for chronic conditions. The trial portfolio spans liver, kidney, neurological, and cancer-related diseases, showing a wide clinical research footprint for a hospital-based site.

  • Safety and tolerability of new therapies
  • Measuring whether treatments improve clinical outcomes
  • Supporting research across several chronic disease areas

With 9 trials and 5 investigators, the site contributes to research that aims to improve both diagnosis and treatment effectiveness across complex long-term illnesses.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida Luis De Camoes Nº 579004-514 FunchalPortugal
Recruiting now
8 trials
Conditions studied
8

More sites in FunchalPortugal

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

Study of Elafibranor for Adults with Primary Biliary Cholangitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Fundacion PETHEMA

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

A Study Comparing MB11 and Nivolumab in Adults With Previously Untreated Advanced or Metastatic Melanoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Mabxience Research S.L.

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study on Long-Term Safety of Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:ABBV-CLS-628
  • Sponsor:Calico Life Sciences LLC
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.